Despite laser photocoagulation therapy, diabetic retinopathy remains a common cause of visual impairment and blindness [1] , principally as a consequence of proliferative retinopathy and macular oedema. Although the pathogenesis of these retinal disorders characterized by retinal neovascularization and exudation is incompletely understood, recent evidence has implicated the vascular endothelial growth factor (VEGF), a permeability-inducing and endothelial cell selective angiogenic glycoprotein as a key factor [2±4].
studies have shown that components of the renin-angiotensin system are also present in the retina [8] and that the severity of retinopathy correlates with the activity of the RAS [9, 10] . More recently, treatment of diabetic patients with the angiotensin converting enzyme inhibitor, lisinopril has been shown to reduce both the rate of progression of non-proliferative retinopathy and the development of proliferative changes [11] .
In vitro studies have shown that angiotensin II (AII) directly stimulates the secretion of VEGF in cultured vascular smooth muscle [12] and in cardiac endothelial cells [13] . Whether this relation between the RAS and VEGF secretion applies to the in vivo setting has not, however, been examined. Accordingly, our study sought to determine whether the beneficial effects of ACE inhibition in experimental diabetic retinopathy is mediated by changes in retinal VEGF expression.
Materials and methods
Animals. Experimental studies were conducted in two stages. Experiment 1 was conducted to determine changes in retinal VEGF gene expression as assessed by northern blot analysis. The aims of Experiment 2 were fourfold. Firstly, to assess the effects of ACE inhibition on retinal vascular permeability. Secondly, to determine the pattern of VEGF mRNA distribution in the eye. Thirdly, to confirm the findings of northern analysis on retinal gene expression using a complimentary technique and fourthly to assess whether another ACE inhibitor, perindopril, had similar effects to those of ramipril.
In Experiment 1, twenty-four male Sprague Dawley (SD) rats aged 8 weeks, weighing between 200 and 250 grams were assigned at random to receive streptozotocin (STZ, n = 12) at a dose of 45 mg/kg (diabetic) or citrate buffer alone (control, n = 12). Both control and STZ-diabetic rats were further selected at random to receive either the ACE inhibitor, ramipril (Hoechst Marion Roussel, Frankfurt, Germany) 1 mg/l in drinking water or untreated drinking water. All rats were given free access to standard chow containing 20 % protein (Clark, King & Co., Melbourne, Australia). Only STZ-treated animals with plasma glucose concentrations above 15 mmol/l were considered diabetic and included in the study. Diabetic animals were treated with 6 units insulin zinc suspension (Ultratard HM, Novo Nordisk, Bagsvaerd, Denmark) injected subcutaneously three times a week to maintain body weight and improve long-term survival. Rats were assigned at random to receive either STZ (n = 12) or citrate buffer (n = 12). Animals were killed at 24 weeks. In the six rats from each group (control, control + ramipril, diabetic, diabetic + ramipril) eyes were enucleated immediately after death and the retinae isolated by blunt dissection using a dissecting microscope. Retinae were then frozen in liquid nitrogen and stored at ±80 C for subsequent northern analysis.
To further assess the effects of ACE inhibition on retinal VEGF expression, another study was done (Experiment 2). As in Experiment 1, rats (n = 48) were assigned at random to receive either STZ (n = 24) or citrate buffer (n = 24). Both control and STZ-diabetic rats were then further selected at random to receive either the ACE inhibitor, perindopril (Servier, Neuilly, France) 2 mg/l in drinking water or untreated drinking water. For 24 h before they were killed animals were housed in metabolic cages for subsequent measurement of urinary albumin excretion rate using a coated tube radioimmunoassay [14] . At 24 weeks, six rats in each of the four groups (control, control with perindopril diabetes, diabetes with perindopril) underwent assessment of vascular permeability. The remaining 24 rats were decapitated after which both eyes were enucleated and blood was collected for measurement of plasma glucose concentration by glucose oxidase technique [15] , haemoglobin A 1 c by HPLC [16] and hematocrit by automated cell counter. The left eye of the remaining six rats in each group was immersion-fixed in 10 % neutral buffered formalin and was subsequently embedded in paraffin for in situ hybridization studies.
All experimentation was approved by the animal ethics committee of the Austin and Repatriation Medical Centre.
Northern blot analysis. Retinae from animals stored at ±80 C, outlined in Experiment 1 were homogenized (Ultra-Turrax, Janke and Kunkel, Staufen, Germany) and total RNA was isolated by the acid guanidinium thiocyanate-phenol-chloroform extraction method [17] . The retina from two rats in the same study group were pooled to yield approximately 20 mg of total RNA. The RNA containing nylon filters were then hybridized with the cDNA encoding mouse VEGF 164 . The VEGF cDNA probe was labelled with [a- 32 P] dCTP by random-primed DNA synthesis (Boehringer Mannheim, Mannheim, Germany) followed by northern analysis [18] . Intensity of hybridization was quantified using a phosphorescent imager (Fujix BASS 3000, Fuji Photo Film Co. Ltd, Tokyo, Japan) and all results were corrected for differences in RNA loading and transfer by rehybridization with an oligonucleotide probe for 18S rRNA. Results were expressed as the ratio of image intensity of VEGF to 18S relative to control retinae which were assigned arbitrarily a value of 1. In addition, hybridized filters were also exposed to x-ray film with intensifying screens (Kodak X-Omat, Eastman Kodak, Rochester, N. Y., USA) at ±80 C for 14 days.
In situ hybridization. In situ hybridization was done using a cDNA encoding mouse VEGF 164 (gift of Dr S. Stacker, Ludwig Institute for Cancer Research, Melbourne, Australia) [19] . The fragment containing the entire open reading frame of VEGF (gift of Dr. S. Stacker) was cloned into pGEM 4Z (Promega, Maddison, Wis., USA) and linearized with Hind III to produce an antisense riboprobe using T7 RNA polymerase. In situ hybridization was as described previously [20] in animals outlined in Experiment 2. After removal of the eye, the globe was embedded in paraffin with the optic nerve head placed at 45 . Retinal sections were then cut perpendicularly from the posterior pole of the globe. The tenth 4 mm section from each rat retina was selected for evaluation of gene expression. These 4 mm thick sections cut from formalin-fixed paraffin-embedded eye tissue were placed onto slides precoated with 3-aminopropyltriethoxysilane and baked overnight at 37 C. In situ hybridization was then done as described previously [21] . Sections hybridized with sense probe for VEGF was used as a control for non-specific binding. After hybridization, slides were washed in 2 SSC, rinsed, incubated with RNAse A, washed again in 2 SSC, dehydrated in graded ethanol, air dried and exposed to Kodak X-Omat autoradiographic film for 5 days. Slides were subsequently dipped in Ilford K5 nuclear emulsion (Ilford, Mobberley, Cheshire, UK), stored in a light-free box with desiccant at room temperature for 2 weeks, immersed in Kodak D19 developer, fixed in Ilford Hypam and stained with haematoxylin and eosin.
Quantitative autoradiography. The gene expression of VEGF was assessed by densitometric evaluation of autoradiographic images. Densitometry of autoradiographic images obtained by in situ hybridization was done by computer-assisted image analysis as described previously [21, 22] according to a reported method [23] using a micro computer imaging device (MCID, Imaging Research, St Catherine's, Ontario, Canada). In brief, in situ autoradiographic images were placed on a uniformly illuminating fluorescent light box (Northern Light Precision Luminator Model C60, Image Research, Ontario, Canada) and captured using a video camera (Sony Video Camera Module CCD, Tokyo, Japan) connected to an IBM AT computer with a 512 512 pixel array imaging board with 256 grey levels. After appropriate calibration by constructing a curve of optical density and radioactivity [24, 25] quantification of digitalized autoradiographic images was done using MCID software. Data were expressed as the ratio [in arbitray units (AU)] of the optical density (OD) relative to control retinae which were assigned a value of 1. Tissue sections from all animals were exposed to x-ray film for 5 days and exposed to photographic emulsion for 14 days. All analyses were done with the observer masked to the animal study group.
Vascular permeability. Vascular permeability was measured at 24 weeks after the induction of experimental diabetes using a double isotope method [26, 27] . In brief, a permeation marker, 125 I-human serum albumin, was injected intravascularly and allowed to circulate for 15 min. This time is adequate to allow passage of the marker from the intravascular to the extravascular space but not in the reverse direction. After 13 min, an intravascular marker, 131 I-human serum albumin was injected and allowed to circulate for the final 2 min of the experiment, permitting the systemic distribution but not extravascular permeation of the marker. We prepared 125 I-albumin by the chloramine-T method [28] . Rats were anaesthetized by intravenous injection of methohexital and amylobarbital. At 1 and 5 min, 0.2 ml of blood was drawn by arterial cannula. At 13 min, 0.56±0.74 MBq of 131 I-albumin was injected intravenously and at 15 min a further blood sample was taken before the lethal injection of pentobarbitone. Ocular tissues were than rapidly removed and dissected to yield choroid-free retina as described previously [27] . The radioisotope content was measured by g-spectroscopy (Crystal 5412/5424, United Technologies, Packard Cleveland, Queensland, Australia), corrected for background and isotope spill-over and related to tissue weight. An error of less than 2 % was obtained by extending the counting period to 10 min. The tissue to blood isotope ratio (TBIR) for retina was calculated from the tissue counts of the intravascular marker, Statistics. Because of a positively skewed distribution albuminuria was logarithmically transformed before statistical analysis and expressed as geometric mean x/ tolerance factor. Results of other variables are expressed as means SEM unless stated otherwise. Data were analysed by ANOVA with comparisons between groups using Fisher's least significant difference method [29] . Analyses were done using the Statview SE + Graphics package (Abacus Concepts, Berkeley, Calif., USA) on an Apple G3 (Apple Computer, Cupertino, Calif., USA). A p value less than 0.05 was considered statistically significant.
Results
Clinical data. In Experiment 1, all animals that had received STZ were diabetic [plasma glucose > 15 mmol/l; plasma glucose: control (C) 6.1 0.1, control + ramipril (CR) 7.8 0.2, diabetic (D) 28.4, diabetes + ramipril (DR) 26.3 0.7 mmol/l; p < 0.001 C, CR vs D, DR]. Glycated haemoglobin was higher in diabetic rats and unaffected by ramipril treatment (C 3.3 0.1, CR 3.4 0.1, D 10.6 0.6, DR 11.1 0.3 %; p < 0.001 C, CR vs D, DR). In ramipriltreated animals systolic blood pressure was similar to control animals and less than in untreated diabetic rats (albumin excretion rate: C 118 4, CR 106 3, D 129 3, DR 113 5, p < 0.01 C vs CR, D vs DR). Similarly, in Experiment 2, rats that had received STZ were also all diabetic with no difference in HbA 1 c between animals perindopril-treated and untreated diabetic animals ( Table 1) . Diabetes was associated with reduced body weight when compared with control animals and was not influenced by treatment with perindopril (Table 1) . Perindopril treatment was, however, accompanied by albumin excretion rates and systolic blood pressure similar to control animals and significantly less than in untreated diabetic rats (Table 1) .
Northern blot analysis. Retinal VEGF gene expression was increased twofold in retinae of diabetic compared with control rats (control: 1.0 0.36 vs diabetic 1.9 0.11 AU, p < 0.05). VEGF mRNA in ramipril- treated diabetic rats was similar to that of control animals (1.1 0.10) and less than in untreated diabetic rats (p < 0.05), (Figs. 1, 2) . No difference in VEGF expression was noted between control and ramipriltreated controls.
In situ hybridization autoradiography. In situ hybridization autoradiography showed an increase in VEGF gene expression in the retina of diabetic rats compared with control animals (control, 166 9 vs diabetic, 252 31 OD units, p < 0.05, Figs. 3 and 4) . This overexpression was reduced in perindopriltreated diabetic rats to levels similar to those of control animals (101 18 OD units, p < 0.01, Figs. 3 and  4) . No difference in VEGF expression was noted between control and perindopril-treated control (132 12 OD units, Figs. 3 and 4) , nor between control and perindopril-treated diabetic rats.
In situ hybridization microscopy. Intense expression of VEGF mRNA was noted in the ganglion cell layer, inner nuclear layer and retinal pigment epithelium (Fig. 5) . There was no change in the pattern of distribution of VEGF mRNA in diabetic and perindopril-treated diabetic rats compared with control animals.
Retinal permeability. Diabetes was associated with a twofold increase in retinal tissue to blood isotope ratio (TBIR) compared with control animals (Fig. 6 ). This diabetes-related retinal hyperpermeability was reduced by perindopril treatment (Fig. 6 ). Perindopril had no effect on TBIR in control rats.
Discussion
In the context of the recent description of the beneficial effects of ACE inhibitors in diabetic retinopathy [11] , it is postulated that these drugs exert their retinoprotective effects through the modulation of VEGF expression. Our findings provide supportive in vivo evidence of an AII-VEGF axis within the retina which could be activated in certain pathological conditions such as diabetes. Furthermore, the inhibition of this pathway was associated with a reduction in retinal vascular hyperpermeability. Although the angiogenic properties of VEGF have been the focus of much recent attention, this polypeptide growth factor was originally described as a tumour secretory product causing vascular leakage [30] . It has been found that VEGF is 50,000 times more potent than histamine as an enhancer of vascular permeability [31] . The role of VEGF in the pathogenesis of diabetic eye disease was initially shown 6 years ago with the finding that intraocular VEGF concentrations in patients with active proliferative retinopathy were statistically significantly higher than in diabetic patients without neovascularization [3, 4] . In addition to being a specific endothelial cell mitogen, VEGF induces an angiogenic response in a variety of in vivo models including rabbit cornea [32] Data are expressed as means SEM of the ratio of optical density (OD) in arbitrary units (AU) for VEGF mRNA relative to that of 18S rRNA. * p < 0.05 vs control, ramipril-treated diabetic rats and ramipril-treated controls and chicken chorioallantoic membrane [33] . Its role in angiogenesis has been further shown by the ability of soluble chimeric VEGF-binding proteins to suppress neovascularization [34] . More recently, examination of retinas from patients with non-proliferative diabetic retinopathy has also shown abundant immunostainable VEGF in the absence of anatomical evidence of retinal non-perfusion [2] . Studies in experimental animals have found VEGF and its receptors in the retina of normoglycaemic animals and also increased expression in association with the diabetic milieu [21, 35, 36] .
Several factors implicated in the pathogenesis of diabetic retinopathy have been shown to increase VEGF expression. These include not only glucose [37] but also advanced glycation end products (AGEs) [38] and protein kinase-C activation [39, 40] . Of particular relevance to our study, angiotensin II also stimulates VEGF expression, an action mediated by the AT1 receptor as indicated by the attenuation of this effect by the AT1 receptor antagonist, losartan [13, 41] . Furthermore, in addition to its effects of on VEGF expression, angiotensin II also increases expression of VEGF Receptor-2 (VEGFR-2) [42] thereby potentially increasing tissue responses to VEGF. In addition, VEGF expression is also regulated by a number of other growth factors including platelet-derived growth factor, transforming growth factor-b [43] and insulin-like growth factor-I (IGF-I) [44] . Recent studies suggest that interactions between IGF-I and its receptors enhance the angiogenic effects of VEGF [45] . These findings are consistent with the documented association between IGF-I and diabetic retinopathy [46] and suggest that both IGF-I and VEGF may contribute to the pathogenesis of vision-threatening retinal disease in diabetes. Thus, although a reduction in VEGF expression with ACE inhibitor treatment was noted in our study it is also possible that other intra-ocular growth factors such as IGF-I were also affected by modulation of the RAS as in the kidney [47] .
Although diabetes in the rodent model is not associated with proliferative retinopathy it does develop increased retinal vascular permeability [27, 48, 49] in association with increased retinal VEGF expression [21, 50] . In adult primates intravitreal injections of VEGF leads to many of the changes associated with non-proliferative diabetic including oedema, microaneurysms and intraretinal haemorrhages [51] suggesting that VEGF has a key role in non-proliferative as well as proliferative retinopathy.
The presence of a local as distinct from a systemic renin-angiotensin system (RAS) has been established in several organ systems [52, 53] including the eye where the presence of all components of the RAS including its receptors have been identified [8, 54±56] . The beneficial effect of ACE inhibition on retinopathy in patients with diabetes was recently shown in the EUCLID study where treatment with lisinopril was associated with a statistically significant reduction in the progression of retinopathy [11] confirming the results of several earlier trials with ACE inhibitors in which the benefits achieved approached but did not reach pre-defined levels of statistical significance [60±62]. Epidemiological, clinical course and intervention studies have all shown a positive relation between blood pressure and both the incidence and progression of diabetic retinopathy [63±65]. Furthermore, cell stretch, an in vitro counterpart of hypertension leads to increased VEGF expression [66] . Thus, it is possible that the effects of ACE inhibition on vascular permeability and VEGF expression, as shown in our study, followed a reduction in systemic blood pressure rather than a specific effect on the RAS.
In our study ACE inhibition reduced the overexpression of VEGF and vascular permeability in the retinas of diabetic rats, providing a potential mechanistic link between diabetes, VEGF and the therapeutic effects of blockade of the renin-angiotensin system in diabetic retinal disease. 
